3,230
Views
13
CrossRef citations to date
0
Altmetric
Original Articles

Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA – descriptive analysis and estimation of 2015 baseline

, , &
Pages 625-637 | Received 10 Dec 2019, Accepted 03 May 2020, Published online: 17 Jun 2020

Figures & data

Table 1. Number of deaths and age-standardised rates per 100,000 population from hepatocellular carcinoma, liver cirrhosis and chronic liver disease as defined by WHO core 10 indicator and chronic viral hepatitis B and C and alcoholic liver disease, by gender, 2015, the EU/EEA countries.

Figure 1. Age-standardised mortality rates per 100,000 population from hepatocellular carcinoma (ICD-10 code C22.0) in the EU/EEA countries in 2015.

Figure 1. Age-standardised mortality rates per 100,000 population from hepatocellular carcinoma (ICD-10 code C22.0) in the EU/EEA countries in 2015.

Figure 2. Age-standardised mortality rates per 100,000 population from chronic liver diseases (ICD-10 codes K72–K75) in the EU/EEA countries in 2015.

Figure 2. Age-standardised mortality rates per 100,000 population from chronic liver diseases (ICD-10 codes K72–K75) in the EU/EEA countries in 2015.

Figure 3. Age-standardised mortality rates per 100,000 population from cirrhosis (ICD-10 codes K74.3–K74.6) in the EU/EEA countries in 2015.

Figure 3. Age-standardised mortality rates per 100,000 population from cirrhosis (ICD-10 codes K74.3–K74.6) in the EU/EEA countries in 2015.

Figure 4. Age-standardised mortality rates per 100,000 population from chronic viral hepatitis B and C (ICD-10 codes B18.0, B18.1 and B18.2) in the EU/EEA countries in 2015.

Figure 4. Age-standardised mortality rates per 100,000 population from chronic viral hepatitis B and C (ICD-10 codes B18.0, B18.1 and B18.2) in the EU/EEA countries in 2015.

Figure 5. Mortality from liver diseases in the EU/EEA in 2015 and the fraction attributable to hepatitis B and C.

Note: Total mortality was calculated by summing up the number of deaths from liver cancer (ICD-10 code C22) and ‘cirrhosis and other chronic liver diseases’ (a broader definition of chronic liver diseases than that of WHO, including ICD-10 codes B18–B18.9, I85–I85.9, I98.2, K70–K70.3, K71.7, K74–K74.9, K75.2, K75.4–K76.2, K76.4–K76.9 and K77.8) extracted from Eurostat for each EU/EEA country. Mortality attributable to HBV and HCV was estimated by adjusting mortality figures for each country with the country-specific aetiology fraction estimates for HBV and HCV available from GBD publications. Overall for the EU/EEA, 45% or cirrhosis and other chronic liver diseases deaths (n = 34,898) and 55% of liver cancer deaths (n = 29,029) could be attributable to HBV and HCV. Baseline mortality attributable to HBV and HCV is thus, 63,927.

Figure 5. Mortality from liver diseases in the EU/EEA in 2015 and the fraction attributable to hepatitis B and C.Note: Total mortality was calculated by summing up the number of deaths from liver cancer (ICD-10 code C22) and ‘cirrhosis and other chronic liver diseases’ (a broader definition of chronic liver diseases than that of WHO, including ICD-10 codes B18–B18.9, I85–I85.9, I98.2, K70–K70.3, K71.7, K74–K74.9, K75.2, K75.4–K76.2, K76.4–K76.9 and K77.8) extracted from Eurostat for each EU/EEA country. Mortality attributable to HBV and HCV was estimated by adjusting mortality figures for each country with the country-specific aetiology fraction estimates for HBV and HCV available from GBD publications. Overall for the EU/EEA, 45% or cirrhosis and other chronic liver diseases deaths (n = 34,898) and 55% of liver cancer deaths (n = 29,029) could be attributable to HBV and HCV. Baseline mortality attributable to HBV and HCV is thus, 63,927.

Table 2. Mortality attributable to HBV and HCV in 2015 in the EU/EEA – number of death from Eurostat adjusted by aetiology fraction (AF) estimates from Global Burden of Disease (GBD).

Table 3. Mortality rates per 100,000 population from hepatocellular carcinoma, cirrhosis and chronic liver diseases as defined by WHO core 10 indicator, and chronic viral hepatitis B and C in the EU/EEA during 2011–2015.

Supplemental material

Supplemental Material

Download MS Word (189.3 KB)